National Stage Entry of PCT/JP03/06959 Attorney Docket No.: Q83579

December 3, 2004

#### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

#### **LISTING OF CLAIMS:**

1. (original): A process for producing an optically active  $\alpha$ -substituted aminoketone represented by formula (4):

$$Ar^{1} \xrightarrow{R^{2}} H \xrightarrow{*^{1}} Ar^{2}$$

$$R^{1} R^{2}$$

$$(4)$$

(wherein  $Ar^1$  and  $Ar^2$  each independently represent a substituted or unsubstituted  $C_6$ - $C_{15}$  aryl group,  $R^1$  represents a  $C_1$ - $C_{12}$  alkyl or  $C_7$ - $C_{12}$  aralkyl group,  $R^2$  represents a  $C_1$ - $C_{12}$  alkyl group, \*1 and \*2 each represent an asymmetric carbon atom) or an optically active  $\alpha$ -substituted aminoketone salt represented by formula (5):

$$Ar^{1} \xrightarrow{R^{2}} R^{2} + Ar^{2}$$

$$R^{1} R^{2}$$
(5)

(wherein Ar<sup>1</sup>, Ar<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, \*1, and \*2 are the same as above, and A<sup>-</sup> represents a counter anion), the process comprising the steps of:

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

reacting an  $\alpha$ -substituted ketone represented by formula (1):

$$Ar^1$$

$$\downarrow L$$

$$\downarrow R^1$$
(1)

(wherein Ar<sup>1</sup> and R<sup>1</sup> are the same as above, and L represents a leaving group) with an optically active amine represented by formula (2):

$$H_2N \xrightarrow{*^1} Ar^2$$

$$R^2$$
(2)

(wherein  $Ar^2$ ,  $R^2$ , and \*1 are the same as above) to yield a mixture of diastereomers of an optically active  $\alpha$ -substituted aminoketone represented by formula (3):

$$Ar^{1} \xrightarrow{R^{1}} Ar^{2}$$

$$R^{1} R^{2}$$
(3)

(wherein Ar1, Ar2, R1, R2, and \*1 are the same as above); and

isolating one diastereomer from the mixture after optionally yielding salts of the diastereomers with an acid.-

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 2. (original): The process according to claim 1, wherein L is a halogen atom.
- 3. (original): The process according to claim 2, wherein the halogen atom is a chlorine atom or bromine atom.
- 4. (currently amended): The process according to any one of claims 1 to 3 claim 1 wherein Ar<sup>2</sup> is a phenyl group or a p-methoxyphenyl group; and R<sup>2</sup> is a methyl group.
- 5. (currently amended): The process according to any one of claims 1 to 4 claim 1, wherein R<sup>1</sup> is a methyl group or an ethyl group.
- 6. (currently amended): The process according to any one of claims 1 to 5 claim 1, wherein, in the step of isolating the diastereomer from the mixture of the diastereomers of the optically active  $\alpha$ -substituted aminoketone represented by formula (3), a crystallization method, a chromatographic method, or a distillation method is employed.
- 7. (currently amended): The process according to any one of claims 1 to 5 claim 1, wherein, in the step of isolating the diastereomer from the mixture of the diastereomers of the optically active  $\alpha$ -substituted aminoketone represented by formula (3), the salts of the

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

diastereomers with the acid are yielded, and the salt of one diastereomer is preferentially

crystallized from a solvent.

8. (original): The process according to claim 7, wherein the acid is sulfonic acid.

9. (original): The process according to claim 8, wherein the sulfonic acid is

methanesulfonic acid.

10. (currently amended): The process according to any one of claims 7 to 9 claim 7,

wherein the solvent is at least one selected from the group consisting of ester solvents, ether

solvents, ketone solvents, halogenated solvents, alcohol solvents, hydrocarbon solvents, nitrile

solvents, and water.

11. (currently amended): The process according to any one of claims 7 to 9 claim 7,

wherein the solvent is ethyl acetate, acetone, or dimethoxyethane.

12. (currently amended): The process according to any one of claims 1 to 11 claim 1,

wherein, in formula (4) or (5), the absolute configuration at \*2 is S and the absolute

configuration at \*1 is R; or the absolute configuration at \*2 is R and the absolute configuration at

\*1 is S.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 13. (original): The process according to claim 7, wherein the acid is hydrogen halide.
- 14. (original): The process according to claim 13, wherein the hydrogen halide is hydrogen chloride or hydrogen bromide.
- 15. (currently amended): The process according to claim 7, 13, or 14, wherein the solvent is an alcohol solvent or water.
- 16. (currently amended): The process according to claim 7, 13, or 14, wherein the solvent is ethanol or a mixture of ethanol and water.
- 17. (currently amended): The process according to any one of claims 13 to 16 claim 13, wherein, in formula (4) or (5), the absolute configuration at \*2 is R and the absolute configuration at \*1 is R; or the absolute configuration at \*2 is S and the absolute configuration at \*1 is S.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

18. (currently amended): A process for producing an optically active  $\beta$ -substituted amino alcohol represented by formula (6) or a salt thereof:

$$Ar^{1} \xrightarrow{*^{2}} \overset{\mathsf{H}}{\overset{*^{2}}{\mathsf{H}}} \overset{\mathsf{H}^{1}}{\overset{\mathsf{H}^{2}}{\mathsf{H}^{2}}} Ar^{2}$$

$$(6)$$

(wherein Ar<sup>1</sup>, Ar<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, \*1, and \*2 are the same as <u>in formula (4) of claim 1 above</u>, and \*3 represents an asymmetric carbon atom), comprising a step of stereoselectively reducing an optically active α-substituted aminoketone represented by formula (4) above of claim 1 produced by the process of claim 1 or an optically active α-substituted aminoketone salt represented by formula (5) above of claim 1 produced by the process of claim 1.

- 19. (currently amended): The process according to claim 18, wherein the <u>step of</u> <u>stereoselectively reducing comprises selectively reducing an anti-isomer is selectively reduced</u> using a boron compound in methanol, ethanol, or a mixture of ethanol and water.
- 20. (original): The process according to claim 19, wherein the boron compound is sodium borohydride.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 21. (currently amended): The process according to any one of claims 18 to 20 claim 18, wherein, in formula (6), the absolute configuration at \*2 is S, the absolute configuration at \*1 is R, and the absolute configuration at \*3 is R; or the absolute configuration at \*2 is R, the absolute configuration at \*1 is R, and the absolute configuration at \*3 is S; or the absolute configuration at \*3 is S; or the absolute configuration at \*3 is S; or the absolute configuration at \*3 is S; and the absolute configuration at \*3 is S; or the absolute configuration at \*3 is R.
- 22. (currently amended): A process for producing an optically active  $\beta$ -amino alcohol represented by formula (7) or a salt thereof:

$$Ar^{1} \xrightarrow{*^{2}} NH_{2}$$

$$R^{1}$$

$$(7)$$

(wherein Ar<sup>1</sup>, R<sup>1</sup>, \*2, and \*3 are the same as <u>in formula (6) of claim 18above</u>), comprising the step of hydrogenolyzing an optically active β-substituted amino alcohol represented by formula (6) or a salt thereof produced by the process of claim 18.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

23. (currently amended): The process according to claim 22, wherein, in formula (6), Ar<sup>1</sup> is a p-hydroxyphenyl group or a hydroxyl-protected p-hydroxyphenyl group represented by formula (10):

(wherein P represents a hydrogen atom or a protecting group protecting the hydroxyl group), and an optically active β-amino alcohol represented by formula (9) or a salt thereof:

(wherein R<sup>1</sup>, \*2, and \*3 are the same as <u>in formula (6)above</u>) is produced by the hydrogenolysis after optionally removing the protecting group protecting the hydroxyl group.

24. (currently amended): The process according to claim 23, wherein P represents a benzyl-containingtype protecting group, an aroyl-containingtype protecting group, or a sulfonyl-containingtype protecting group.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 25. (currently amended): The process according to any one of claims 22 to 24 claim 23, wherein, in formula (9), the absolute configuration at \*2 is S and the absolute configuration at \*3 is S; or the absolute configuration at \*2 is R and the absolute configuration at \*3 is S.
- 26. (currently amended): A process of producing an optically active β-amino alcohol represented by formula (7) above or a salt thereof:

$$Ar^{1} \xrightarrow{*^{2}} NH_{2}$$

$$R^{1}$$

$$(7)$$

(wherein Ar<sup>1</sup> represents a substituted or unsubstituted  $C_6$ - $C_{15}$  aryl group,  $R^1$  represents a  $C_1$ - $C_{12}$  alkyl or  $C_7$ - $C_{12}$  aralkyl group, and \*2 and \*3 each represents an asymmetric carbon atom, comprising:

stereoselectively reducing while simultaneously performing a hydrogenolysis of , wherein an optically active  $\alpha$ -substituted aminoketone represented by formula (4)-above:

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

$$Ar^{1}$$
 $X^{2}$ 
 $X^{2}$ 
 $X^{1}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{4}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{4}$ 
 $X^{2}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{4}$ 
 $X^{2}$ 
 $X^{4}$ 
 $X^{2}$ 
 $X^{3}$ 
 $X^{4}$ 
 $X^{4}$ 
 $X^{2}$ 
 $X^{4}$ 
 $X^{$ 

(wherein Ar<sup>1</sup>, R<sup>1</sup> and \*2 are the same as in formula (7), Ar<sup>2</sup> represents a substituted or unsubstituted  $C_6$ - $C_{15}$  aryl group, R<sup>2</sup> represents a  $C_1$ - $C_{12}$  alkyl group and \*1 represents an asymmetric carbon atom)

or of an optically active α-substituted aminoketone salt represented by formula (5) above:

(wherein Ar<sup>1</sup>, Ar<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, \*1, and \*2 are the same as in formula (4), and A<sup>-</sup> represents a counter anion) is stereoselectively reduced while simultaneously performing the hydrogenolysis.

27. (currently amended): The process according to claim 26, wherein the anti-isomer is selectively reduced by hydrogenation in the presence of a transition metal catalyst while simultaneously performing the hydrogenolysis.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 28. (original): The process according to claim 27, wherein the transition metal catalyst comprises palladium-carbon or palladium(II) hydroxide-carbon.
- 29. (currently amended): The process according to any one of claims 26 to 28 claim 26, wherein an optically active  $\alpha$ -substituted aminoketone represented by formula (11) or a salt thereof:

$$P = \begin{pmatrix} & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

(wherein  $R^1$ ,  $R^2$ ,  $Ar^2$ , \*1; and\*2 are the same as in formula (4), and P represents a protecting group protecting the hydroxyl group are the same as above) is stereoselectively reduced while simultaneously performing the hydrogenolysis after removing the protecting group protecting the hydroxyl group to yield an optically active  $\beta$ -amino alcohol represented by formula (9) above-or a salt thereof

(wherein R<sup>1</sup> and \*2 are the same as in formula (11), and \*3 represents an asymmetric carbon atom).

- 30. (currently amended): The process according to claim 29, wherein P is a benzyl-containing type protecting group, an aroyl-containing type protecting group, or a sulfonyl-containing type protecting group.
- 31. (currently amended): The process according to any one of claims 26 to 30 claim 29, wherein in formula (9), the absolute configuration at \*2 is S and the absolute configuration at \*3 is S; or the absolute configuration at \*2 is R and the absolute configuration at \*3 is S.
- 32. (currently amended): The process according to any one of claims 26 to 31 claim 26, wherein the optically active  $\alpha$ -substituted aminoketone represented by formula (4) or the optically active  $\alpha$ -substituted aminoketone salt represented by formula (5) are produced by the process comprising the steps of:

reacting an  $\alpha$ -substituted ketone represented by formula (1):

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

$$Ar^1$$
 $L$ 
 $R^1$ 
 $(1)$ 

(wherein Ar<sup>1</sup> and R<sup>1</sup> are the same as in formula (4), and L represents a leaving group) with an optically active amine represented by formula (2):

$$H_2N \xrightarrow{*^1} Ar^2$$

$$R^2$$
(2)

(wherein Ar<sup>2</sup>, R<sup>2</sup>, and \*1 are the same as in formula (4) to yield a mixture of diastereomers of an optically active  $\alpha$ -substituted aminoketone represented by formula (3):

$$Ar^{1} \xrightarrow{R^{1}} Ar^{2}$$

$$R^{1} R^{2}$$
(3)

(wherein Ar<sup>1</sup>, Ar<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, and \*1 are the same as above); and

<u>diastereomers with an acid of claim 1 is used as the starting material.</u>

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

33. (original): A process for isolating an optically active  $\alpha$ -substituted aminoketone salt represented by formula (5):.

$$Ar^{1} \xrightarrow{R^{1}} R^{2} Ar^{2}$$

$$R^{1} R^{2} A^{-}$$
(5)

(wherein  $Ar^1$  and  $Ar^2$  each independently represent a substituted or unsubstituted  $C_6$ - $C_{15}$  aryl group,  $R^1$  represents a  $C_1$ - $C_{12}$  alkyl or  $C_7$ - $C_{12}$  aralkyl group,  $R^2$  represents a  $C_1$ - $C_{12}$  alkyl group, \*1 and \*2 each represent an asymmetric carbon atom, and A- represents a counter anion), comprising the steps of:

yielding salts from an acid and a mixture of diastereomers of an optically active  $\alpha$ substituted aminoketone represented by formula (3):

$$Ar^{1} \xrightarrow{R^{1}} R^{2}$$
 (3)

(wherein Ar<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, Ar<sup>2</sup>, and \*1 are the same as above); and

preferentially crystallizing the salt of one diastereomer from a solvent.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

34. (original): The isolation process according to claim 33, wherein the acid is sulfonic acid.

35. (original): The isolation process according to claim 34, wherein the sulfonic acid is methanesulfonic acid.

36. (original): The isolation process according to claim 34 or 35, wherein the solvent is at least one selected from ester solvents, ether solvents, ketone solvents, halogenated solvents, alcohol solvents, hydrocarbon solvents, nitrile solvents, and water.

37. (original): The isolation process according to claim 34 or 35, wherein the solvent is ethyl acetate, acetone, or dimethoxyethane.

38. (currently amended): The isolation process according to any one of claims 34 to 37 claim 34, wherein, in formula (5), the absolute configuration at \*2 is S and the absolute configuration at \*1 is R; or the absolute configuration at \*2 is R and the absolute configuration at \*1 is S.

39. (original): The isolation process according to claim 33, wherein the acid is hydrogen halide.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 40. (original): The isolation process according to claim 39, wherein the hydrogen halide is hydrogen chloride or hydrogen bromide.
- 41. (original): The isolation process according to claim 39 or 40, wherein the solvent is an alcohol solvent or water.
- 42. (original): The isolation process according to claim 39 or 40, wherein the solvent is ethanol or a mixture of ethanol and water.
- 43. (currently amended): The isolation process according to any one of claims 39 to 42 claim 39, wherein, in formula (5), the absolute configuration at \*2 is R and the absolute configuration at \*1 is R; or the absolute configuration at \*2 is S and the absolute configuration at \*1 is S.
- 44. (currently amended): The isolation process according to any one of claims 33 to 43 claim 33, wherein Ar<sup>2</sup> is a phenyl group or a p-methoxyphenyl group; and R<sup>2</sup> is a methyl group.
- 45. (currently amended): The isolation process according to any one of claims 33 to 44 claim 33, wherein R<sup>1</sup> is a methyl group or an ethyl group.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 46. (currently amended): The isolation process according to any one of claims 33 to 45 claim 33, wherein Ar<sup>1</sup> is a phenyl group, a p-hydroxyphenyl group, a p-benzyloxyphenyl group, or a p-methanesulfonyloxyphenyl group.
- 47. (currently amended): An optically active  $\alpha$ -substituted aminoketone represented by formula (4) above

wherein  $Ar^1$  and  $Ar^2$  each independently represent a substituted or unsubstituted  $C_6$ - $C_{15}$  aryl group,  $R^2$  represents a  $C_1$ - $C_{12}$  alkyl group, \*1 and \*2 each represent an asymmetric carbon atom and  $R^1$  is a  $C_1$ - $C_4$  alkyl group or a  $C_7$ - $C_{12}$  aralkyl group, or

an optically active α-substituted aminoketone salt represented by formula (5) above

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

$$Ar^{1} \xrightarrow{R^{2}} H_{2} + Ar^{2}$$

$$+ + + Ar^{2}$$

wherein  $Ar^1$ ,  $Ar^2$ ,  $R^1$ ,  $R^2$ , \*1, and \*2 are the same as above, and  $A^2$  represents a counter anion  $R^4$  is a  $C_4$ - $C_4$ -alkyl group or a  $C_2$ - $C_{12}$ -aralkyl group.

- 48. (original): The optically active  $\alpha$ -substituted aminoketone or the optically active  $\alpha$ -substituted aminoketone salt according to claim 47, wherein, in formula (4) or (5), Ar<sup>2</sup> is a phenyl or p-methoxyphenyl group, and R<sup>2</sup> is a methyl group.
- 49. (currently amended): The optically active  $\alpha$ -substituted aminoketone or the optically active  $\alpha$ -substituted aminoketone salt according to claim 47 or 48, wherein, in formula (4) or (5), R<sup>1</sup> is a methyl group or an ethyl group.
- 50. (currently amended): The optically active  $\alpha$ -substituted aminoketone or the optically active  $\alpha$ -substituted aminoketone salt according to any one of claims 47 to 49 claim 47, wherein, in formula (4) or (5), Ar<sup>1</sup> is a phenyl group, a p-hydroxyphenyl group, a p-benzyloxyphenyl group, a p-benzyloxyphenyl group, or a p-methanesulfonyloxyphenyl group.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

51. (currently amended): The optically active  $\alpha$ -substituted aminoketone or the optically

active α-substituted aminoketone salt according to any one of claims 47 to 50 claim 47, wherein,

in formula (4) or (5), the absolute configuration at \*2 is S and the absolute configuration at \*1 is

R; or the absolute configuration at \*2 is R and the absolute configuration at \*1 is S.

52. (currently amended): The optically active  $\alpha$ -substituted aminoketone salt according

to any one of claims 47 to 51 claim 47, wherein A- in formula (5) is a methanesulfonate ion.

53. (currently amended): The optically active  $\alpha$ -substituted aminoketone or the optically

active α-substituted aminoketone salt according to any one of claims 47 to 50 claim 47, wherein,

in formula (4) or (5), the absolute configuration at \*2 is R and the absolute configuration at \*1 is

R; or the absolute configuration at \*2 is S and the absolute configuration at \*1 is S.

54. (currently amended): The optically active  $\alpha$ -substituted aminoketone salt according

to any one of claims 47 to 50 and 53 claim 47, wherein A- in formula (5) is a chlorine ion or a

bromine ion.

55. (original): An optically active β-substituted amino alcohol represented by formula

(8) or a salt thereof:

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

$$P \xrightarrow{R^1} R^2 \qquad (8)$$

(wherein  $R^1$  represents a  $C_1$ - $C_{12}$  alkyl or  $C_7$ - $C_{12}$  aralkyl group,  $Ar^2$  represents a substituted or unsubstituted  $C_6$ - $C_{15}$  aryl group,  $R^2$  represents a  $C_1$ - $C_{12}$  alkyl group, \*1, \*2, and \*3 each represent an asymmetric carbon atom, and P represents a hydrogen atom or a protecting group protecting the hydroxyl group).

- 56. (original): The optically active  $\beta$ -substituted amino alcohol or the salt thereof according to claim 55, wherein  $Ar^2$  is a phenyl group or a p-methoxyphenyl group, and  $R^2$  is a methyl group.
- 57. (original): The optically active  $\beta$ -substituted amino alcohol or the salt thereof according to claim 55 or 56, wherein R<sup>1</sup> is a methyl group or an ethyl group.
- 58. (currently amended): The optically active β-substituted amino alcohol or the salt thereof according to any one of claims 55 to 57 claim 55, wherein P is a benzyl-containing type protecting group, an aroyl-containing type protecting group, or a sulfonyl-containing type protecting group.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

- 59. (currently amended): The optically active β-substituted amino alcohol or the salt thereof according to any one of claims 55 to 57 claim 55, wherein P is a benzyl group, and benzoyl group, or a methanesulfonyl group.
- 60. (currently amended): The optically active β-substituted amino alcohol or the salt thereof according to any one of claims 55 to 59 claim 55, wherein, in formula (8), the absolute configuration at \*2 is S, the absolute configuration at \*1 is R, and the absolute configuration at \*3 is R; or the absolute configuration at \*2 is R, the absolute configuration at \*1 is R, and the absolute configuration at \*3 is S; or the absolute configuration at \*2 is R, the absolute configuration at \*1 is S, and the absolute configuration at \*3 is S; or the absolute configuration at \*3 is R.
- 61. (currently amended): A process for isolating an optically active  $\beta$ -amino alcohol represented by formula (9) or a salt thereof with an optically inactive acid from a mother liquor:

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

(wherein R<sup>1</sup> represents a C<sub>1</sub>-C<sub>12</sub> alkyl or C<sub>7</sub>-C<sub>12</sub> aralkyl group, and \*2 and \*3 each represent an

asymmetric carbon atom), comprising a step of crystallizing the optically active β-amino alcohol

represented by formula (9) or the salt thereof with the optically inactive acid from an alcohol

solvent to remove impurities contained therein to the mother liquor to thereby obtain crystals of

the optically active β-amino alcohol represented by formula (9) or the salt thereof with the

optically inactive acid.

62. (original): The isolation process according to claim 61, wherein R<sup>1</sup> is a methyl group

or an ethyl group.

63. (currently amended): The isolation process according to claim 61 or 62, wherein the

alcohol solvent is methanol, ethanol, or isopropanol.

64. (currently amended): The isolation process according to any one of claims 61 to 63

claim 61, wherein an auxiliary solvent is used to improve at least one of the yield of the

compound represented by formula (9) above, the process concentration, the liquid properties, and

the physical properties of the crystals obtained.

65. (original): The isolation process according to claim 64, wherein the auxiliary solvent

is at least one selected from the group consisting of ester solvents, ether solvents, ketone

solvents, halogenated solvents, hydrocarbon solvents, and nitrile solvents.

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

66. (original): The isolation process according to claim 64, wherein the auxiliary solvent

is ethyl acetate or methylene chloride.

67. (currently amended): The isolation process according to any one of claims 64 to 66

claim 64, wherein the volume ratio of the auxiliary solvent to the alcohol solvent upon

completion of the process for crystallization is 1 or more.

68. (currently amended): The isolation process according to any one of claims 61 to 67

claim 61, wherein, the compound represented by formula (9) has the S absolute configuration at

\*2 and the R absolute configuration at \*3 and the impurity to be removed is either its

diastereomer (having the S absolute configuration at \*2 and the S absolute configuration at \*3)

or its enantiomer (having the R absolute configuration at \*2 and the S absolute configuration at

the \*3); or the compound represented by formula (9) has the R absolute configuration at \*2 and

the S absolute configuration at \*3 and the impurity to be removed is either its diastereomer

(having the R absolute configuration at \*2 and the R absolute configuration at \*3) or its

enantiomer (having the S absolute configuration at \*2 and the R absolute configuration at the

\*3).

69. (currently amended): The isolation process according to any one of claims 61 to 68-A

process for isolating an optically active  $\beta$ -amino alcohol represented by formula (9) or a salt

thereof with an optically inactive acid from a mother liquor:

National Stage Entry of PCT/JP03/06959

Attorney Docket No.: Q83579

December 3, 2004

(wherein  $R^1$  represents a  $C_1$ - $C_{12}$  alkyl or  $C_7$ - $C_{12}$  aralkyl group, and \*2 and \*3 each represents an asymmetric carbon atom),

comprising a step of crystallizing the optically active  $\beta$ -amino alcohol represented by formula (9) or the salt thereof with the optically inactive acid from an alcohol solvent to remove impurities contained therein to the mother liquor to thereby obtain crystals of the optically active  $\beta$ -amino alcohol represented by formula (9) or the salt thereof with the optically inactive acid, wherein the optically active.  $\beta$ -amino alcohol represented by (9) is produced by the method of claim 23 or 29 is used as a starting material.

70. (currently amended): The isolation process according to any one of claims 61 to 69 claim 61, wherein the optically inactive acid is hydrogen chloride, hydrogen bromide, or methanesulfonic acid.